Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.71019 ↗At a glance
Journal article in Pediatric Pulmonology, 2025. Written by Yaron Fireizen and 18 co-authors. Institution: Department of Pediatrics, Rady Children's Hospital, University of California San Diego, San Diego, California, USA. Major MEDLINE topics: Cystic Fibrosis, Hospitalization. Cited 9 times so far (Crossref); 38 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS, This research was supported by a Cystic Fibrosis Foundation student traineeship award to MA (AHMED23H0). EB was supported by 1K23HL169902-01..
Abstract (original language)
Rationale
The introduction of elexacaftor/tezacaftor/ivacaftor (ETI), a highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, to younger ages and the COVID‐19 pandemic have significantly reduced pulmonary exacerbations requiring hospitalization among children with CF.
Objective
To assess demographic and clinical characteristics of children and young adults with CF hospitalized for pulmonary exacerbations before and after pediatric ETI approval.
Methods
A retrospective chart review was conducted at five United States CF Foundation‐accredited care centers. Hospitalization data from children and young adults with CF in 2018 and 2022 were analyzed.
Results
Hospitalizations decreased from 471 cases (241 individuals) in 2018 to 163 cases (110 individuals) in 2022. The racial distribution shifted, with more hospitalized patients identifying as people of color in 2022 (28% vs. 14%; p = 0.018). A greater proportion of hospitalized children in 2022 had two non‐F508del mutations compared with children hospitalized in 2018 (38% vs. 19%) and were less likely to be infected with methicillin‐resistant Staphylococcus aureus (MRSA). Comparing 2022−2018, children on CFTR modulator therapy, including ETI (76%), showed reduced infections with Pseudomonas aeruginosa and Achromobacter xylosoxidans .
Conclusions
The decline in hospitalizations for pulmonary exacerbations likely reflects the benefits of ETI therapy, as a higher proportion of children and young adults hospitalized in 2022 had two non‐F508del mutations and were not eligible for ETI. A greater percentage of those hospitalized in 2022 identified as belonging to minority racial groups, highlighting ongoing health disparities in the ETI era. Additionally, there were notable changes in the microbiological characteristics between 2018 and 2022.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, Rady Children's Hospital, University of California San Diego, San Diego, California, USA.
- University of Colorado School of Medicine, Aurora, Colorado, USA.
- Department of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Pediatrics, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
- Center for Genetic Medicine Research, Children's National Research Institute, Washington, District of Columbia, USA.
Funding
- NHLBI NIH HHS
- This research was supported by a Cystic Fibrosis Foundation student traineeship award to MA (AHMED23H0). EB was supported by 1K23HL169902-01.
Cite
APA
Fireizen, Y., Ahmed, M., Vigers, T., Akong, K., Ryu, J., Hahn, A., Fanous, H., Koumbourlis, A., Tirakitsoontorn, P., Arrieta, A., Burgener, E. B., Koff, J., Cogen, J. D., Bouzek, D. C., Hanley, E., Keck, A., Stout, D., Bradley, J., & Sagel, S. D. (2025). Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71019
Vancouver
Fireizen Y, Ahmed M, Vigers T, Akong K, Ryu J, Hahn A, et al. Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71019
BibTeX
@article{Fireizen2025,
author = {Fireizen, Yaron and Ahmed, Mohamoud and Vigers, Timothy and Akong, Kathryn and Ryu, Julie and Hahn, Andrea and Fanous, Hani and Koumbourlis, Anastassios and Tirakitsoontorn, Pornchai and Arrieta, Antonio and Burgener, Elizabeth B and Koff, Jonathan and Cogen, Jonathan D and Bouzek, Drake C and Hanley, Elin and Keck, Allison and Stout, Dayna and Bradley, John and Sagel, Scott D},
title = {Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.71019}
}
EUVIMED